Developing small-molecule immunotherapies for cancer and inflammatory diseases
Current cancer immunotherapies benefit only a subset of patients, and some solid tumours still lack adequate treatments. Patients who do not respond to approved immunotherapies, or cannot access complex cellular therapies, need alternative or combination approaches.
Adoram Therapeutics develops small molecules that tune the adenosine A2A receptor. Its preclinical programmes aim to boost immune attacks on solid tumours or reduce inflammation, using different ways of modulating the same receptor.
What stands out about Adoram Therapeutics
Venture Kick records a European patent granted for the A2AR NAM solid-tumour immunotherapy in August 2025.
The company reports human in vitro responses and in vivo proof of mode of action in high-adenosine mouse models.
Secured pre-seed investment from private business angels, Ipalmetrix and FONGIT, announced in 2025.
Secured a CHF 1.05 million Innosuisse research grant for its anti-inflammatory programme with University of Geneva groups.
Spun out of the University of Geneva to develop allosteric small-molecule therapies for cancer and inflammation.
Collaborates with University of Geneva groups led by Leonardo Scapozza and Cem Gabay on its Innosuisse-backed anti-inflammatory programme.
Founders bring doctorates and research expertise in immunology, pharmacology, medicinal chemistry and drug discovery.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.